surpass 6 tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6) New Dual Incretin Agonist for

The study commenced July 2022 with primary completion in March 2024 and estimated overall completion by September 2025, conducted at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, demonstrating successful achievement of its primary efficacy endpoint in the induction Phase (62), as announced by the pharmaceutical company, while results are yet to be published

Summary: Ozempic (semaglutide) is not officially recognised as causing anxiety based on current UK regulatory data and clinical trials, though occasional patient reports exist without established causation

10.1111/bcp.14528 [DOI] [PubMed] [Google Scholar] Kagan L

Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE

The GIP receptor pathway plays a distinct role in energy expenditure and glucose metabolism

The strength stays